⌘K
t
Solvonis Therapeutics plc announced on 05 June 2025 that it completed the synthesis of development candidates for its SVN-SDN-014 programme, marking the third of seven stages in the translational development plan. This programme was previously AWKN-SDN-014, prior to Solvonis' acquisition of Awakn Life Sciences Corp. which completed on 27 May 2025. Remaining stages include in-vitro screening expected to complete by the end of July 2025 and lead candidate selection expected by the end of Q3 2025.
| Date | 5 Jun 2025 |
| Time | 07:00:13 |
| Category | Corporate updates |
| ID | 5149L |
("Solvonis" or the "Company")
Synthesis of development candidates for SVN-SDN-014 programme
Further to the Company's announcement on 18 March 2025, Solvonis Therapeutics plc (LSE: SVNS), a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders, provides a progress update on its preclinical programme, SVN-SDN-014 (the "Programme"), a novel series of serotonin ("SERT"), dopamine ("DAT"), and noradrenaline ("NET") modulators in development for trauma-related mental health conditions, including Post-Traumatic Stress Disorder ("PTSD"). Prior to the Company's acquisition of Awakn Life Sciences Corp., which completed on 27 May 2025, the Programme was previously referred to as AWKN-SDN-014.
The Programme aims to develop a new class of medicines for PTSD which affects an estimated 13 million adults in the United States alone, with the Company estimating a total affected population of approximately 20 million across the United States, United Kingdom and key other European markets.
The SVN-SDN-014 series is designed to enhance pro-social behaviour and is being developed with the aim of delivering an improved safety profile compared to existing investigational treatments for PTSD. By modulating neurochemical pathways associated with trust, empathy, and social bonding, the compounds aim to support patients in rebuilding interpersonal relationships, reducing isolation, and engaging more effectively in therapy.
The Company has now completed the synthesis of development candidates, marking the third of seven stages in the SVN-SDN-014 translational development plan. This latest phase involved the synthesis of a focused set of compounds for subsequent preclinical characterisation, including pharmacological and toxicological profiling.
The remaining stages for the programme are as follows:
1. In-vitro screening for SERT, DAT and NET re-absorption inhibition
2. In-vitro screening for SERT, DAT and NET release - expected to complete by the end of July 2025
3. Pre-clinical animal testing
4. Lead candidate selection - expected by the end of Q3 2025
Further details of the remaining stages can be found in the Company's announcement on 18 March 2025.
Anthony Tennyson, Chief Executive Officer of Solvonis, commented: "SVN-SDN-014 represents a novel, mechanism-driven approach to treating PTSD, an area of significant and persistent clinical need. With candidate synthesis now complete, we are progressing the programme toward formal lead selection and IND-enabling studies."
Further updates will be provided as the Programme advances toward regulatory submission.
Enquiries:
Solvonis Therapeutics plc
Anthony Tennyson, CEO & Executive Director
anthony@solvonis.com
Allenby Capital Limited (Financial Adviser and Joint Broker)
Nick Naylor / Nick Athanas / Ashur Joseph (Corporate Finance)
Guy McDougall (Sales & Corporate Broking)
+44 (0) 20 3328 5656
Singer Capital Markets (Joint Broker)
Phil Davies
+44 (0) 20 7496 3000
About Solvonis Therapeutics plc
Solvonis Therapeutics plc (LSE: SVNS) is a clinical-stage biopharmaceutical company developing novel medicines for addiction and mental health disorders. Headquartered in London and listed on the main market of the London Stock Exchange, Solvonis is advancing a differentiated pipeline of repurposed and novel compounds that target high-burden neuropsychiatric conditions with significant unmet need.
The Company's lead programs address Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD)-conditions affecting over 80 million people across the UK, US, and EU4. Its lead asset, SVN-001, is currently in Phase 3 trials for severe AUD in Europe and the UK. SVN-002 is preparing for a Phase 2b trial in the US targeting moderate to severe AUD. Solvonis also has a preclinical PTSD program leveraging novel serotonin-dopamine modulators designed to enhance pro-social behaviour and long-term outcomes.
With a capital-efficient model, dual development strategy, and near-term partnering opportunities, Solvonis is positioned to generate value through innovation in neuropsychiatry.